2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells

Gynecologic Oncology

Volumn 76, Issue 2, 2000, Pages 183-192

  Kushner, David M ^a   Paranjape, Jayashree M ^a   Bandyopadhyay, Bhaswati ^a   Cramer, Hagen ^b   Leaman, Douglas W ^b   Kennedy, Alexander W ^a   Silverman, Robert H ^a   Cowell, John K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Gemini Technologies Inc   (United States)

Author keywords

2 5A; Antisense; Ovarian cancer; Telomerase

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; RIBONUCLEASE; TELOMERASE;

APOPTOSIS; ARTICLE; CANCER CELL; CHIMERA; CONTROLLED STUDY; GENE TARGETING; GLIOMA CELL; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA CLEAVAGE;

EID: 0033980773     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5668     Document Type: Article

References (34)

1. Gewirtz A M, Sokol D L, Ratajczak M Z. Nucleic acid therapeutics: state of the art and future prospects. Blood. 92:1998;712-736.
2. Flanagan M W. Antisense comes of age. Cancer Met Rev. 17:1998;169-176.
3. Torrence P F, Maitra R K, Lesiak K, Khamnei S, Zhou A, Silverman R H. Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proc Natl Acad Sci USA. 90:1993;1300-1304.
4. Zhou A, Hassel B A, Silverman R H. Expression cloning of 2-5A-dependent RNase - a uniquely regulated mediator of interferon action. Cell. 72:1993;753-765.
5. Cirino N M, Li G, Xiao W, Torrence P F, Silverman R H. Targeting RNA decay with 2′,5′-oligoadenylate-antisense in respiratory syncytial virus infected cells. Proc Natl Acad Sci USA. 94:1997;1937-1942.
6. Maran A, Waller C F, Paranjape J M, Li G, Xiao W, Zhang K, Kalaycio M E, Maitra R K, Lichtin A E, Brugger W, Torrence P F, Silverman R H. 2′5′Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells. Blood. 92:1998;4336-4343.
7. Kondo S, Kondo Y, Li G, Silverman R H, Cowell J K. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene. 16:1998;3323-3330.
8. Greider C W. Telomere length regulation. Annu Rev Biochem. 65:1996;337-365.
9. Bodnar A G, Ouellette M, Frolkis M, Holt S E, Chiu C P, Morin G B, Shay J W, Lichtsteiner S, Wright W E. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
10. Feng J, Funk W D, Sy-Shi W, Weinrich S L, Avilion A A, Choy-Pik C, Adams R R, Chang E, Allsopp R C, Yu J, Le S, West M D, Harley C B, Andrews W H, Greider C W, Villeponteau B. The RNA component of human telomerase. Science. 269:1995;1236-1241.
11. Lingner J, Hughes T R, Shevchenko A, Mann M, Lundblad V, Cech T R. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science. 276:1997;561-567.
12. Norton J C, Piatyszek M A, Wright W E, Shay J W, Corey D R. Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol. 14:1996;615-679.
13. Pitts A E, Corey D R. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc Natl Acad Sci USA. 95:1998;11549-11554.
14. Counter C M, Hirte H W, Bacchetti S, Harley C B. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA. 91:1994;2900-2904.
15. Wan M, Li W Z, Duggan B D, Felix J C, Zhao Y, Dubeau L. Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst. 89:1997;437-441.
16. Gorham H, Yoshida K, Sugino T, Marsh G, Manek S, Charnock M, Tarin D, Goodison S. Telomerase activity in human gynaecological malignancies. J Clin Pathol. 50:1997;501-504.
17. Murakami J, Nagai N, Ohama K, Tahara H, Ide T. Telomerase activity in ovarian tumors. Cancer. 80:1997;1085-1092.
18. Kyo S, Takakura M, Murakami K, Saitoh R, Hirano H, Inoue M. Quantitative differences in telomerase activity among malignant, premalignant, and benign ovarian lesions. Clin Cancer Res. 4:1998;399-405.
19. Duggan B D, Wan M, Yu M C, Roman L D, Muderspach L I, Delgadillo E, Li W Z, Martin S E, Dubeau L. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J Natl Cancer Inst. 90:1998;238-242.
20. Buick R N, Pullano R, Trent J M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45:1985;3668-3676.
21. Baumal R, Law J, Buik R N, Kahn H, Yeger H, Sheldon K, Colgan T, Marks A. Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line. Cancer Res. 46:1986;3994-4000.
22. Silverman R H, Krause D. Interferon-regulated 2-5A and protein kinase systems. Lymphokines and Interferons: Practical Approach. 1987;IRL Press, Oxford. p. 149-193.
23. Dong B, Silverman R H. 2-5A dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem. 270:1995;4133-4137.
24. Xiao W, Player M R, Li G, Zhang K, Lesiak K, Torrence P F. Synthesis and characterization of composite nucleic acids containing 2′,5′-oligoriboadenylate linked to antisense DNA. Antis Nucl Acid Drug Dev. 6:1996;247.
25. Zuker M. Computer prediction of RNA structure. Methods Enzymol. 180:1989;262-288.
26. Freier S M, Kierzek R, Jaeger J A, Sugimoto N, Caruthers M H, Neilson T, Turner D H. Improved free-energy parameters for predictions of RNA duplex stability. Proc Natl Acad Sci USA. 83:1986;9373-9377.
27. Silverman, R, H, 2-5A dependent RNase L: a regulated endoribonuclease in the interferon system, in, Ribonucleases: Structure and Functions, San Diego, Academic Press, 1997, pp, 515, - 551.
28. Leaman D W, Cramer H. Controlling gene expression with 2-5A antisense. Methods. 18:1999;252-265.
29. Gavrieli Y, Sherman Y, Ben-Sasson S A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
30. Wang L, Zhou A, Vasavada S, Dong B, Nie H, Church J M, Williams B RG, Banerjee S, Silverman R H. Elevated levels of 2′,5′-linked oligoadenylate-dependent ribonuclease L occur as an early event in colorectal tumorigenesis. Clin Cancer Res. 1:1995;1421-1428.
31. Blasco M A, Lee H W, Hande M P, Samper E, Lansdorp P M, DePinho R A, Greider C W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:1997;25-34.
32. Zakian V A. Life and cancer without telomerase. Cell. 91:1997;1-3.
33. Lee H W, Blasco M A, Gottlieb G J, Horner J W, Greider C W, DePinho R A. Essential role of mouse telomerase in highly proliferative organs. Nature. 392:1998;569-574.
34. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1999;1321-1325.